Lisa • January 10, 2023
A Man Called Otto

A true MUST-see for the HCM Community.

Today I should be calling my sister and signing… “when I’m 64”, but instead, I will remember the beautiful soul we lost when she was only 36.

Yesterday I went to see the new movie “A Man called Otto”, in this movie, Tom Hanks character Otto has HCM. I haven’t been to the movies much, but I needed to see how the subject was addressed. I did this on the eve of what should have been my sister’s birthday.

I have had HCM since 12 and lost 5 close relatives or more to HCM, and I found Tom Hanks performance 100% accurate, authentic, and raw reality.

At the end of the movie, which I purposely went to alone, I sat in a dark theater as the credits ran and cried (I’m not a crier). Not only was the depiction of HCM so real, but it also reminded me of the countless number of HCM warriors I’ve had the honor and privilege of knowing, supporting, advocating for, and loving since we lost Lori. The movie was the first time I had seen my family (bio and community) so accurately depicted. It touched my soul. Thank you, Mr. Hanks for being remarkable at your craft.

HCMA Blog

Pro Publica Releases Results of FDA Investigation

By Erica Friedman • June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts